PVLA PALVELLA THERAPEUTICS, INC.

company

SEC Filings & Insider Trading Activity 2026

Risk Factors

• • No new or changed risk factors from 2024 Form 10-K disclosed this quarter
• • Regulatory/legal risk focus unchanged; no new defaults or safety disclosures reported

What are the latest PVLA SEC filings in 2026?

PALVELLA THERAPEUTICS, INC. (PVLA) has filed a 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 12, 2025, an 8-K current report on April 13, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did PVLA file its most recent 10-K annual report?

PALVELLA THERAPEUTICS, INC. (PVLA) filed its most recent 10-K annual report on March 31, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view PVLA 10-Q quarterly reports?

PALVELLA THERAPEUTICS, INC. (PVLA)'s most recent 10-Q quarterly report was filed on November 12, 2025. SignalX displays every PVLA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has PVLA filed recently?

PALVELLA THERAPEUTICS, INC. (PVLA)'s most recent 8-K was filed on April 13, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find PVLA insider trading activity (Form 4)?

SignalX aggregates every PVLA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does PVLA file with the SEC?

PALVELLA THERAPEUTICS, INC. (PVLA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PVLA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for PALVELLA THERAPEUTICS, INC. (PVLA).

What is PVLA's SEC CIK number?

PALVELLA THERAPEUTICS, INC. (PVLA)'s SEC CIK (Central Index Key) number is 1583648. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1583648 to look up all PVLA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find PVLA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from PALVELLA THERAPEUTICS, INC. (PVLA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.